DNA barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and in response to immunotherapy [DNA barcodes: All_EMT6_BC5000]

To investigate immunoediting at the primary tumour, we used DNA barcoding combined with NGS. By stably integrating EMT6 murine cancer cell line with 5000 unique DNA barcodes (1 barcode per cell), we can trace how barcode (and therefore subclonal) diversity changes over time and after treatment with immunotherapy. Overall design: The data provided are generated by targeted barcode sequencing of primary tumours generated in mice from barcoded EMT6 cells. Samples are generated from 6 severely immunocompromised (NSG) mice, 5 wildtype (immunocompetent) control treated mice, and 6 wildtype immunotherapy treated mice. One sample is generated from the cell pellet left over after surgery